23:32 , Aug 15, 2019 |  BC Innovations  |  Translation in Brief

New target bolsters TREM2's role in Alzheimer's

A new gene linked to TREM2 reinforces the microglial receptor's role in Alzheimer's and could offer a way to treat the disease. As the Alzheimer's field looks beyond β amyloid for new pathways and targets,...
00:26 , Jul 20, 2019 |  BC Extra  |  Clinical News

July 19 Clinical Quick Takes: Polyphor closes Phase III murepavadin trials; plus Takeda and Alector

Polyphor ends PRISM trials  The Swiss immuno-oncology company Polyphor AG (SIX:POLN) closed the Phase III PRISM MDR and PRISM UDR trials of its IV formulation of murepavadin for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) after...
02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
22:39 , Jul 9, 2019 |  BC Extra  |  Company News

July 9 Company Quick Takes: Celgene, Nimbus expand deal; plus Gilead-Lyndra, Darzalex and more

Celgene gets option for Nimbus' HPK1 program  Celgene Corp. (NASDAQ:CELG) expanded its partnership with Nimbus Therapeutics LLC (Cambridge, Mass.) to include an option for the latter's HPK1 inhibitor to treat cancer, which Celgene can exercise...
01:33 , Apr 19, 2019 |  BC Innovations  |  Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...
23:14 , Apr 11, 2019 |  BC Innovations  |  Targets & Mechanisms

A venture view of biological white space

Scanning the horizon of translational research, VCs on BioCentury’s scientific advisory board see innate neuroinflammation as a white space area flush with under-tapped angles for drug development, and think the rise of single cell-level data...
12:44 , Mar 21, 2019 |  BC Innovations  |  Emerging Company Profile

A Passage to optimal CNS vectors

Passage is arming itself with AAV vectors, gene therapies and non-human primate studies from gene therapy pioneer James Wilson at UPenn to develop disease-modifying treatments for rare monogenic diseases affecting the CNS. The company launched...
23:30 , Feb 13, 2019 |  BC Week In Review  |  Financial News

Harpoon slips after pricing $75.6M IPO

Harpoon Therapeutics Inc. (NASDAQ:HARP) raised $75.6 million in an IPO that priced at the midpoint of its proposed range. Harpoon sold 5.4 million shares at $14, within the $13-$15 range. The price gave Harpoon a...
04:00 , Feb 8, 2019 |  BC Extra  |  Financial News

Harpoon slips after pricing $75.6M IPO

Harpoon Therapeutics Inc. (NASDAQ:HARP) shares lost $0.50 to $13.50 in their first day of trading Friday after the company raised $75.6 million in an IPO that priced at the midpoint of its proposed range. Harpoon...
01:56 , Feb 8, 2019 |  BC Week In Review  |  Financial News

Immuno-neurology company Alector dips after $175.8M IPO

Alector Inc. (NASDAQ:ALEC) raised $175.8 million in an IPO to support clinical trials of a handful of antibodies for neurologic indications including frontotemporal dementia and Alzheimer's disease. The immuno-neurology company sold 9.3 million shares at...